Citation Impact
Citing Papers
2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer
2015 Standout
Stress and the Brain: A Paradoxical Role for Adrenal Steroids
1995
Severe impairment of bone mass and turnover in Cushing’s disease: comparison between childhood‐onset and adulthood‐onset disease
2002
Reversal of acromegalic cardiomyopathy in young but not in middle‐aged patients after 12 months of treatment with the depot long‐acting somatostatin analogue octreotide
2003
Thiazolidinediones
2004 Standout
Clinical and pathophysiological consequences of abdominal adiposity and abdominal adipose tissue depots
2003
Acromegaly
2006 Standout
Abdominal obesity and metabolic syndrome
2006 StandoutNature
Restoration of the coupling process and normalization of bone mass following successful treatment of endogenous Cushing’s syndrome: A prospective, long-term study
2005
The Antitumoral Effects of Somatostatin Analog Therapy in Acromegaly
2005
Inflammation and metabolic disorders
2006 StandoutNature
Thyroid cancer
2016 Standout
Cardiac Effect of Thyrotoxicosis in Acromegaly1
2000
Pharmacotherapy or Surgery as Primary Treatment for Acromegaly?
2000
Stress- and treatment-induced elevations of cortisol levels associated with impaired declarative memory in healthy adults
1996
Cognitive Function and Cerebral Assessment in Patients Who Have Cushing's Syndrome
2005
Increased oxidative stress in obesity and its impact on metabolic syndrome
2004 Standout
Mechanisms linking obesity with cardiovascular disease
2006 StandoutNature
Nonsurgical approaches to the management of thyroid nodules
2006
The Thyroid Nodule
2004 Standout
The metabolic syndrome
2010 Standout
Cushing's syndrome
2015 Standout
Is the Acromegalic Cardiomyopathy Reversible? Effect of 5-Year Normalization of Growth Hormone and Insulin-Like Growth Factor I Levels on Cardiac Performance*
2001
Fibrosis and Adipose Tissue Dysfunction
2013 Standout
Adipocytes as regulators of energy balance and glucose homeostasis
2006 StandoutNature
A Variation in 3′ UTR of hPTP1B Increases Specific Gene Expression and Associates with Insulin Resistance
2002
GPR120 Is an Omega-3 Fatty Acid Receptor Mediating Potent Anti-inflammatory and Insulin-Sensitizing Effects
2010 Standout
Towards harmonisation of outcome measures for DMD and SMA within TREAT-NMD; Report of three expert workshops: TREAT-NMD/ENMC Workshop on outcome measures, 12th–13th May 2007, Naarden, The Netherlands; TREAT-NMD Workshop on outcome measures in experimental trials for DMD, 30th June–1st July 2007, Naarden, The Netherlands; Conjoint Institute of Myology TREAT-NMD Meeting on physical activity monitoring in neuromuscular disorders, 11th July 2007, Paris, France
2008
Acromegaly
1990
Paradoxical Enhancement of Pituitary Growth Hormone (GH) Responsiveness to GH-Releasing Factor in the Face of High Somatostatin Tone*
1989
Comparison between Six-Year Therapy with Long-Acting Somatostatin Analogs and Successful Surgery in Acromegaly: Effects on Cardiovascular Risk Factors
2006
Thyroid Volume and Serum Thyroglobulin Levels in Patients with Acromegaly: Correlation with Plasma Insulin-Like Growth Factor I Levels*
1988
Osteoporosis: now and the future
2011 Standout
Submandibular salivary gland volume is increased in patients with acromegaly
2002
Therapeutic Efficacy of the Somatostatin Analog SMS 201-995 (Octreotide) in Acromegaly
1990
Cabergoline in acromegaly: a renewed role for dopamine agonist treatment?
1998
Improvement of left ventricular hypertrophy and arrhythmias after lanreotide-induced GH and IGF-I decrease in acromegaly. A prospective multi-center study
2002
Macrophage-specific PPARγ controls alternative activation and improves insulin resistance
2007 StandoutNature
Hypothalamic–pituitary–adrenal axis function and corticosterone receptor expression in behaviourally characterized young and aged Long–Evans rats
2001
Increased arterial intima‐media thickness by B‐M mode echodoppler ultrasonography in acromegaly
2001
Hypoxia and the extracellular matrix: drivers of tumour metastasis
2014 StandoutNobel
Treatment of infantile-onset spinal muscular atrophy with nusinersen: a phase 2, open-label, dose-escalation study
2016 Standout
Acromegaly
1994
Glucocorticoids, hippocampal corticosteroid receptor gene expression and antidepressant treatment: relationship with spatial learning in young and aged rats
1995
The metabolic syndrome
2005 Standout
Obesity and Cardiovascular Disease: A Scientific Statement From the American Heart Association
2021 Standout
Diet–microbiota interactions as moderators of human metabolism
2016 StandoutNature
Effect of a six-month treatment with lanreotide on cardiovascular risk factors and arterial intima-media thickness in patients with acromegaly
2002
Cardiovascular Complications in Acromegaly: Methods of Assessment
2001
The Study of the Effects of Diet on Metabolism and Nutrition (STEDMAN) weight loss project: Rationale and design
2005
Protective and Damaging Effects of Stress Mediators
1998 Standout
Cabergoline addition to depot somatostatin analogues in resistant acromegalic patients: efficacy and lack of predictive value of prolactin status
2004
Effect of ingestion of glucose on GH and TSH secretion: Evidence for stimulation of somatostatin release from the hypothalamus by acute hyperglycemia in normal man and its impairment in acromegalic patients
1989
The impact of fat distribution on the severity of nonalcoholic fatty liver disease and metabolic syndrome
2007
Cardiovascular Consequences of Early-Onset Growth Hormone Excess
2002
Brown adipose tissue thermogenic adaptation requires Nrf1-mediated proteasomal activity
2018 StandoutNobel
Mechanisms linking obesity to insulin resistance and type 2 diabetes
2006 StandoutNature
Osteoclast differentiation and activation
2003 StandoutNature
Growth-hormone and prolactin excess
1998
Effect of glucocorticoids on the paradoxical growth hormone response to thyrotropin-releasing hormone in patients with acromegaly
1995
ACROMEGALY
1987
The Metabolic Phenotype in Obesity: Fat Mass, Body Fat Distribution, and Adipose Tissue Function
2017 Standout
β-Arrestin1 mediates nicotinic acid–induced flushing, but not its antilipolytic effect, in mice
2009 StandoutNobel
Reactive oxygen species have a causal role in multiple forms of insulin resistance
2006 StandoutNature
Effect of 2 years of cortisol normalization on the impaired bone mass and turnover in adolescent and adult patients with Cushing's disease: a prospective study
2003
GROWTH HORMONE NEUROREGULATION AND ITS ALTERATIONS IN DISEASE STATES
1988
Macrophage plasticity and polarization: in vivo veritas
2012 Standout
Bone mineral density at diagnosis and following successful treatment of pediatric Cushing’s disease
2005
What We Talk About When We Talk About Fat
2014 Standout
Mechanisms for Insulin Resistance: Common Threads and Missing Links
2012 Standout
Lipid overload and overflow: metabolic trauma and the metabolic syndrome
2003
Cushing's syndrome
2006 Standout
Thyrotropin and Thyroid Cancer Diagnosis: A Systematic Review and Dose-Response Meta-Analysis
2012
Macrophage biology in development, homeostasis and disease
2013 StandoutNature
Ultrasonographic evaluation of thyroid nodules: comparison of ultrasonographic, cytological, and histopathological findings
2009
Effect of Different Dopaminergic Agents in the Treatment of Acromegaly
1997
Growth hormone and the heart
2001
Transplantation of adipose tissue and stem cells: role in metabolism and disease
2010
Glucose Homeostasis and Safety in Patients with Acromegaly Converted from Long-Acting Octreotide to Pegvisomant
2005
Obesity is associated with macrophage accumulation in adipose tissue
2003 Standout
Inflammation, metaflammation and immunometabolic disorders
2017 StandoutNature
Prediabetes: a high-risk state for diabetes development
2012 Standout
Guidelines for Acromegaly Management
2002
Pituitary Tumor Registry: A Novel Clinical Resource1
2000
THYROID ULTRASOUND
2001
Bone loss is more severe in primary adrenal than in pituitary-dependent Cushing?s syndrome
2004
The Many Roles of Chemokines and Chemokine Receptors in Inflammation
2006 Standout
In Vitro Effect of Dopamine and L-Dopa on Prolactin and Growth Hormone Release from Human Pituitary Adenomas*
1979
Occurrence of ventricular late potentials in patients with active acromegaly
2001
Pathophysiology of the Neuroregulation of Growth Hormone Secretion in Experimental Animals and the Human*
1998 Standout
Diagnosis and Management of the Metabolic Syndrome
2005 Standout
Endocrine Therapy of Breast and Prostate Cancer
1989
Abnormal Plasma Catecholamine Responses in Acromegalics
1979
Beneficial Effects of High Daily Dose Bromocriptine Treatment in Cushing's Disease.
1992
Growth Hormone Receptor Antagonists: Discovery, Development, and Use in Patients with Acromegaly
2002
Management of Simple Nodular Goiter: Current Status and Future Perspectives
2003
Tirzepatide Once Weekly for the Treatment of Obesity
2022 Standout
The Roles of Osteoprotegerin and Osteoprotegerin Ligand in the Paracrine Regulation of Bone Resorption
2000
Type 2 diabetes: principles of pathogenesis and therapy
2005 Standout
Growth Hormone Releasing Hormone-Sensitive Adenylate Cyclase Activity in Growth Hormone-Producing Pituitary Adenoma: Correlation to the Response of Plasma Growth Hormone to Growth Hormone Releasing Hormone in Patients with Acromegaly.
1989
AN ASSESSMENT OF GLUCOSE INTOLERANCE IN ACROMEGALY AND ITS RESPONSE TO MEDICAL TREATMENT
1980
Increase in Urinary Cortisol Excretion and Memory Declines: MacArthur Studies of Successful Aging1
1997
Bone Resorption by Osteoclasts
2000 StandoutScience
The effects of putative 5-hydroxytryptamine receptor active agents ond-amphetamine self-administration in controls and rats with 5,7-dihydroxytryptamine median forebrain bundle lesion
1984
Systemic Complications of Acromegaly: Epidemiology, Pathogenesis, and Management
2004 Standout
Characterization of the paradoxical growth hormone inhibitory effect of galanin in acromegaly.
1995
Suppression of Rat and Human Growth Hormone and Prolactin Secretion by a Novel Somatostatin/Dopaminergic Chimeric Ligand
2003
Relationship between Disease-Related Morbidity and Biochemical Markers of Activity in Patients with Acromegaly
2005
Cabergoline in the Treatment of Acromegaly: A Study in 64 Patients
1998
Osteoporosis Is More Prevalent in Adrenal than in Pituitary Cushing's Syndrome.
2003
Maternal Care, Hippocampal Glucocorticoid Receptors, and Hypothalamic-Pituitary-Adrenal Responses to Stress
1997 StandoutScience
Inhibitory effect of octreotide on growth hormone-induced IGF-I generation and organ growth in hypophysectomized rats
1991
Evaluation and application of a highly sensitive assay for serum growth hormone (GH) in the study of adult GH deficiency.
1995
Increased Prevalence of Radiological Spinal Deformities in Active Acromegaly: A Cross-Sectional Study in Postmenopausal Women
2005
Selective Hippocampal Lesions Do Not Increase Adrenocortical Activity
2003 StandoutNobel
Treatment of Large Cold Benign Thyroid Nodules Not Eligible for Surgery with Percutaneous Ethanol Injection
1998
Role of Dopamine in the Regulation of Growth Hormone Secretion: Dopamine and Bromocriptine Augment Growth Hormone (GH)-Releasing Hormone-Stimulated GH Secretion in Normal Man
1987
Growth Factors and Cancer
1991 StandoutScience
Long-Term Treatment of Acromegaly with the Somatostatin Analogue SMS 201–995
1985
Cardiovascular Effects of Depot Long-Acting Somatostatin Analog Sandostatin LAR in Acromegaly*
2000
Pretreatment with somatostatin analog SMS 201-995 potentiates growth hormone (GH) responsiveness to GH-releasing factor in short children.
1993
Obesity is associated with macrophage accumulation in adipose tissue
2003 Standout
Lanreotide 60 mg, a New Long-Acting Formulation: Effectiveness in the Chronic Treatment of Acromegaly
2003
Demonstration of Enhanced Potency of a Chimeric Somatostatin-Dopamine Molecule, BIM-23A387, in Suppressing Growth Hormone and Prolactin Secretion from Human Pituitary Somatotroph Adenoma Cells
2002
A Critical Analysis of Pituitary Tumor Shrinkage during Primary Medical Therapy in Acromegaly
2005
Stimulation of Osteoprotegerin Ligand and Inhibition of Osteoprotegerin Production by Glucocorticoids in Human Osteoblastic Lineage Cells: Potential Paracrine Mechanisms of Glucocorticoid-Induced Osteoporosis1
1999
Somatostatin and Somatostatin Analogue (SMS 201-995) in Treatment of Hormone-Secreting Tumors of the Pituitary and Gastrointestinal Tract and Non-Neoplastic Diseases of the Gut
1989
Nonalcoholic Fatty Liver Disease
2015 Standout
Treatment of Recurrent Thyroid Cysts with Ethanol: A Randomized Double-Blind Controlled Trial
2003
Impact of Glucose Intolerance and Insulin Resistance on Cardiac Structure and Function
2003
Basal cortisol levels and cognitive deficits in human aging
1994
Leptin's Role in Lipodystrophic and Nonlipodystrophic Insulin-Resistant and Diabetic Individuals
2013
Cocaine Receptors on Dopamine Transporters Are Related to Self-Administration of Cocaine
1987 StandoutScience
Cardiovascular Function in Acromegaly
2003
Triglyceride accumulation protects against fatty acid-induced lipotoxicity
2003 Standout
High Prevalence of Cardiac Valve Disease in Acromegaly: An Observational, Analytical, Case-Control Study
2003
Works of Antonio Liuzzi being referenced
The brain as a target for adrenocortical steroids: Cognitive implications
1992
Bone mineral density in acromegaly: Does growth hormone excess protect against osteoporosis?
2001
Clinical results of long‐term slow‐release lanreotide treatment of acromegaly
1997
Prevalence of thyroid diseases in patients with acromegaly: results of an Italian Multi-center Study
2002
Microprolactinomas: Why requiem for surgery?
1996
Radioiodine and Percutaneous Ethanol Injection in the Treatment of Large Toxic Thyroid Nodule: A Long-Term Study
2000
Relationship between blood pressure and glucose tolerance in acromegaly
2001
Evaluation of a Multisensor Armband in Estimating Energy Expenditure in Obese Individuals
2006
Glucose homeostasis in acromegaly: effects of long‐acting somatostatin analogues treatment
2003
Alterations of Bone Turnover and Bone Mass at Different Skeletal Sites due to Pure Glucocorticoid Excess: Study in Eumenorrheic Patients with Cushing’s Syndrome
1998
Serum leptin concentration in moderate and severe obesity: relationship with clinical, anthropometric and metabolic factors
1999
Feasibility of air plethysmography (BOD POD) in morbid obesity: a pilot study
2003
Heart rate behavior during an exercise stress test in obese patients
2008
Bone mineral density in acromegaly: the effect of gender, disease activity and gonadal status
2003
Thyroid hypoechogenicity after methimazole withdrawal in Graves' disease: a useful index for predicting recurrence?
1996
CV 205-502 in acromegaly
1993
Thyroperoxidase Microsatellite Polymorphism in Thyroid Diseases
1995
Leptin plasma concentrations are dependent on body fat distribution in obese patients
2000
Percutaneous Ethanol Injection of Large Thyroid Cystic Nodules
1996
High prevalence of risk factors for cardiovascular disease in parents of IDDM patients with albuminuria
1997
Systemic Hypertension and Impaired Glucose Tolerance Are Independently Correlated to the Severity of the Acromegalic Cardiomyopathy1
2000
Permanence of molecular features of obesity in subcutaneous adipose tissue of ex-obese subjects
2013
Subcutaneous Abdominal Adipose Tissue Subcompartments: Potential Role in Rosiglitazone Effects
2008
Cushing’s disease and marked hyperprolactinemia in a patient with a pituitary macroadenoma: effectiveness of bromocriptine treatment
1984
Molecular and morphologic characterization of superficial‐ and deep‐subcutaneous adipose tissue subdivisions in human obesity
2013
The value of plasma prolactin levels in the prediction of the responsiveness of growth hormone secretion to bromocriptine and TRH in acromegaly
1982
Stable Reduction of Plasma Growth Hormone (hGH) Levels During Chronic Administration of 2-Br-α-ergocryptine (CB-154) in Acromegalic Patients
1975
Investigations of Thyroid Hormones and Antibodies in Obesity: Leptin Levels Are Associated with Thyroid Autoimmunity Independent of Bioanthropometric, Hormonal, and Weight-Related Determinants
2010
Chronic Treatment of Pathological Hyperprolactinemia and Acromegaly with the New Ergot Derivative Terguride*
1986
LONG-TERM TREATMENT WITH 2—Br—α—ERGOCRYPTINE IN ACROMEGALY
1977
The role of prolactin in the inhibitory action of bromocriptine on growth hormone secretion in acromegaly
1983
Relationship between Somatomedin-C and Growtyh Hormone Levels in Acromegaly: Basal and Dynamic Evaluation*
1986
INHIBITORY EFFECT OF L-DOPA ON GH RELEASE IN ACROMEGALIC PATIENTS1
1972
Inhibitory Effect of Dopaminergic Stimulation on GH Release in Acromegaly
1974
Growth Hormone-Releasing Hormone Infusion in Patients with Active Acromegaly
1986
DECREASED PLASMA GROWTH HORMONE (GH) LEVELS IN ACROMEGALICS FOLLOWING CB 154(2-Br-α-ERGOCRYPTINE) ADMINISTRATION1
1974
Serum Type III Procollagen Propeptide Levels in Acromegalic Patients*
1986
Low Doses of Dopamine Agonists in the Long-Term Treatment of Macroprolactinomas
1985
Growth Hormone (GH)-Releasing Activity of TRH and GH-Lowering Effect of Dopaminergic Drugs in Acromegaly: Homogeneity in the Two Responses
1974
EVIDENCE FOR A DOPAMINERGIC ACTIVITY OF METHYSERGIDE IN HUMANS
1977
Medical Treatment of Acromegaly with SMS 201-995, a Somatostatin Analog: A Comparison with Bromocriptine*
1987
Dopaminergic Treatment of Acromegaly: Different Effects on Hormone Secretion and Tumor Size *
1984
Changes in Growth Hormone (GH) Secretion Induced by Human Pancreatic GH Releasing Hormone-44 in Acromegaly: A Comparison with Thyrotropin-Releasing Hormone and Bromocriptine*
1985
Bromocriptine Does Not Alter Growth Hormone (GH) Responsiveness to GH-Rreleasing Hormone in Accromegaly*
1986
Skeletal Involvement in Female Acromegalic Subjects: The Effects of Growth Hormone Excess in Amenorrheal and Menstruating Patients
1997
EFFECT OF DOPAMINE INFUSION ON PLASMA LEVELS OF GROWTH HORMONE IN NONMAL SUBJECTS AND IN AGROMEGALIC PATIENTS
1976